The science is here. The capital isn’t. Digital is a chance for Poland to close the gap.
We mapped forty Polish biotech and pharma companies — from generics giants to clinical-stage innovators to the new wave of CDMOs. The picture that emerged is a genuine industry running into a hard ceiling: too little growth capital to build lasting value the way the US or Western Europe does. This is the argument for a different route to scale — one that doesn’t wait for the capital to arrive.
01 The starting point
A real engine — at a rounding-error scale
Polish pharma exports have climbed from €3.5bn to nearly €4.9bn in four years. The momentum is real. The problem is everything around it stays small on the global map.
Polish pharmaceutical exports (€ billions)
| Label | Value |
|---|---|
| 2019 | 3.54 |
| 2020 | 4.23 |
| 2021 | 4.66 |
| 2022 | 4.45 |
| 2023 | 4.86 |
- 0.6% of global pharma exports — the world's 22nd-largest exporter. Real, but a sliver.
- 40th on the WIPO Global Innovation Index 2024 — behind Switzerland, the US and Korea.
- ~9% growth a year. The base isn't the problem; the ceiling is. And the ceiling is set by capital.
02 The capital trap
Two economies, two destinies
Split the field by profitability and it cleaves in two: cash generators that throw off profit, and innovators that burn it for years. The trouble is that the two halves rarely fund each other.
- Cash-generative. Generics, OTC, diagnostics and devices print profit — Aflofarm alone cleared PLN 316m.
- Clinical-stage. Innovators like Ryvu and Celon run structural losses for years, funded by grants and dilutive raises — not revenue.
- The trap. The profitable half rarely backs frontier R&D, so Poland's most ambitious science runs on grants and hope.
Net result, latest financial year (PLN millions)
03 The capital trap
The money isn't here — and we under-spend on R&D
Private capital could bridge the gap between the two economies. It largely doesn't reach this region — and at the national level, Poland invests the least of the players it hopes to compete with.
Share of global biotech VC, 2025
R&D intensity (% of GDP)
| Label | Value |
|---|---|
| S. Korea | 4.96% |
| USA | 3.45% |
| EU avg | 2.24% |
| Poland | 1.56% |
62 cents of every biotech VC dollar goes to the US. Almost none reaches our region. It’s the structural fact every Polish founder plans around.
Survive, hit a milestone, or sell
When growth capital is scarce, behaviour follows. Founders are pushed toward early exits and milestone payouts — not the patient, compounding value-creation that capital-rich ecosystems can afford.
PLN 1.695bn
Diagnostyka IPO
The first big Main-Market listing of 2025 — a diagnostics success, not a frontier-drug one.
up to $170m
Scope Fluidics → Bio-Rad
Sold its breakthrough PCR|ONE platform rather than scaling it independently.
12–18 mo
Typical cash runway
Clinical-stage firms race the next raise against the next readout, year after year.
Milestones and exits — not lasting value. That is what under-capitalisation buys. So how do you build durable value when capital is thin? The honest answer isn’t more money. It’s a different operating model.
05 The pivot
The frontier nobody has won yet
A digital-capability scorecard across six dimensions that mirror how the industry measures maturity. On every axis, Poland trails. But look closer — the race is wide open.
Digital-capability scorecard (0–100)
- Only 1–3% of pharma worldwide is truly "Pharma 4.0." No incumbent is finished.
- The US leads on data, AI and capital; leading Asia leads on automation and manufacturing.
- Poland/CEE trails everywhere — but its one relative strength is digital talent, the seed to build on.
- Behind ≠ out. The digital frontier is still open.
Zero world-class digital factories in our region
The WEF's "Lighthouse" factories are the global benchmark for digital, AI-driven manufacturing. In pharma and biotech, there are about twenty worldwide — and none in Central and Eastern Europe.
~20 · 0
pharma & biotech Lighthouses worldwide — and zero in CEE
We simply haven't entered the field.
74 / 172
all-sector Lighthouses are in China alone
For context — this headline spans every industry, not just pharma.
Pharma & biotech Lighthouse factories, by region
| Label | Value |
|---|---|
| W. Europe | 11 |
| Asia | 6 |
| USA | 3 |
| CEE | 0 |
Poland’s single Lighthouse, in any sector, is a food plant — we haven’t entered the field.
07 The lever
Digital is the highest-ROI lever we have
For an under-capitalised industry, digital is the cheapest way to expand capacity: it lifts margin and throughput without new capital. The improvement ranges aren't marginal.
Reduction achievable with Pharma 4.0 (%)
- 5,000–45,000 manual entries sit in a single paper batch record.
- ~91% accuracy is all you get before a product ships — paper erodes the rest.
- Same money, more output. Killing the paper is not glamorous — it's the cheapest margin in the building.
Each win aimed at a Polish pain point
Digital isn't an abstraction here. Four concrete capabilities map directly onto the structural constraints we found across the forty companies.
Optimised operations
Pain · thin generics margins & loss-making R&D
MES, predictive maintenance and automation cut cost-of-goods.
Faster scaling
Pain · tiny capital, slow clinical & plant scale-up
Digital tech-transfer and cloud labs scale capacity without scaling cost.
Transparency
Pain · investor & regulator trust gap vs US/EU
Real-time data and electronic records make quality auditable end-to-end.
Standardisation
Pain · fragmented, paper-based, bespoke processes
Common digital platforms make output repeatable and CDMO-ready.
09 Where to start
Where the first euro should go
Not everywhere at once. Map digital maturity against profitability — bubble size is revenue, colour is company type — and the priority pops out: profitable companies that are still digital laggards pay back fastest.
Digital maturity × profitability × revenue
- Fastest payback: profitable makers — Aflofarm, Adamed, Polpharma — still stuck at "digital silos."
- The test-bed: CDMOs like Rezon Bio and Mabion already run modern, single-use, data-rich plants.
- Runway, not margin: loss-making innovators (Ryvu, Celon) need digital to extend runway first.
A three-horizon path — and what it needs
Digitise first to build the data spine, integrate to predict and connect, then reach for autonomy. None of it lands without the ecosystem behind it.
Digitise
Horizon 1 · 0–12 months
Electronic batch records (MES) and lab/LIMS connectivity. Kill paper, build the data spine.
Integrate
Horizon 2 · 1–3 years
Predictive quality & maintenance, plant-wide analytics (L3→L4), a CDMO-grade digital handshake.
Automate
Horizon 3 · 3 years +
AI in discovery & operations, digital twins, real-time release. Scale without scaling cost.
- What it needs: growth capital, CDMO partners, EMA pathways and regional hubs — the ecosystem behind the technology.
11 The takeaway
It took 20+ years to build polish biotech. The decade ahead must focus on techbio - driven by digital.
The science is real and the manufacturing base is real. What's missing is capital — and the digital backbone that lets an under-capitalised industry compete without it.
1.56%
R&D / GDP today
The least of the players we hope to beat.
~0%
of global biotech VC reaches our region
Out of a ~$38bn pool.
0 → 1
the goal: the first world-class digital biotech factory in CEE
Catch-up is a choice — digital is how we make it.
Build the first one with A4BEE.